American Society of Hirudotherapy

Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial

Randomized controlled trial published in Critical Care (2014)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialClinical LiteratureDrug DevelopmentSafety & Infection ControlTreschan TA et al. · Critical Care, 2014

Abstract

INTRODUCTION: Critically ill patients often require renal replacement therapy accompanied by thrombocytopenia. Thrombocytopenia during heparin anticoagulation may be due to heparin-induced thrombocytopenia with need for alternative anticoagulation. Therefore, we compared argatroban and lepirudin in critically ill surgical patients. METHODS: Following institutional review board approval and written informed consent, critically ill surgical patients more than or equal to 18 years with suspected heparin-induced thrombocytopenia, were randomly assigned to receive double-blind argatroban or lepirudin anticoagulation targeting an activated Partial Thromboplastin Time (aPTT) of 1.5 to 2 times baseline. In patients requiring continuous renal replacement therapy we compared the life-time of hemodialysis filters. We evaluated in all patients the incidence of bleeding and thrombembolic events. RESULTS: We identified 66 patients with suspected heparin-induced thrombocytopenia, including 28 requiring renal replacement therapy. Mean filter lifetimes did not differ between groups (argatroban 32 ± 25 hours (n = 12) versus lepirudin 27 ± 21 hours (n = 16), mean difference 5 hours, 95% CI -13 to 23, P = 0.227). Among all 66 patients, relevant bleeding occurred in four argatroban- versus eleven lepirudin-patients (OR 3.9, 95% CI 1.1 to 14.0, P = 0.040). In the argatroban-group, three thromboembolic events occurred compared to two in the lepirudin group (OR 0.7, 95% CI 0.1 to 4.4, P = 0.639). The incidence of confirmed heparin-induced thrombocytopenia was 23% (n = 15) in our study population. CONCLUSIONS: This first randomized controlled double-blind trial comparing two direct thrombin inhibitors showed comparable effectiveness for renal replacement therapy, but suggests fewer bleeds in surgical patients with argatroban anticoagulation. TRIAL REGISTRATION: Clinical Trials.gov NCT00798525. Registered 25 November 2008.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov't
Indexed MeSH termsAgedAged, 80 and overAnticoagulantsAntithrombinsArginineCritical IllnessFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedPartial Thromboplastin TimePipecolic AcidsRecombinant ProteinsRenal InsufficiencyRenal Replacement TherapySulfonamidesSurgical Procedures, OperativeThrombocytopenia

Summary

First randomized double-blind trial comparing two direct thrombin inhibitors in 66 critically ill surgical patients with suspected HIT: argatroban and lepirudin showed comparable hemodialysis-filter lifetimes, but the trial suggests fewer bleeding events with argatroban than lepirudin (4 vs 11 patients, OR 3.9).

Why This Matters for Hirudotherapy

This randomized controlled double-blind trial compared argatroban and lepirudin in 66 critically ill surgical patients with suspected heparin-induced thrombocytopenia, targeting an aPTT of 1.5 to 2 times baseline. Among 28 patients requiring continuous renal replacement therapy, hemodialysis filter lifetimes were comparable between groups, but relevant bleeding occurred significantly more often with lepirudin (11 events) than argatroban (4 events; OR 3.9, P = 0.040). The abstract does not describe lepirudin's relationship to hirudin or mention leeches, so a hirudotherapy connection is not supported by the abstract text. Only 23% had confirmed HIT, and the sample is relatively small, which may limit generalizability.

Citation

Reference (Vancouver style)

Treschan TA, Schaefer MS, Geib J, Bahlmann A, Brezina T, Werner P, et al. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial. Crit Care. 2014;18(5):588. doi:10.1186/s13054-014-0588-8. PMID: 25344113

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.